In line with preclinical data, clinical studies evaluating G-CSF expression on tumour cells have also shown an association with aggressive clinicopathological features and poor prognosis in solid organ malignancies such as clear cell renal cell carcinomas and cervical cancers [14,15]. This evidence concerns the gene CSF3 and cervical cancer.